Pre-op MMC effective for recurrent pterygium

Article

Subconjunctival mitomycin C (MMC) injections followed by bare sclera pterygium excision is successful and cost-effective for the treatment of recurrent pterygium associated with symblepharon, according to a recently published study.

Subconjunctival mitomycin C (MMC) injections followed by bare sclera pterygium excision is successful and cost-effective for the treatment of recurrent pterygium associated with symblepharon, according to a recently published case study

Dr Isyaku Mohammed et al., Department of Ophthalmology, Aminu Kano Teaching Hospital, Kano, Nigeria, conducted a case report on a 31-year-old male with recurrent pterygium.

Low-dose (0.02%) MMC was administered to the patient one month before bare sclera excision of multicurrent pterygium. At the same time, symblepharolysis was performed including further application of MMC intraoperatively to the upper conjunctival fornix.

Overall, MMC injections followed by excision are cost-effective and easily performed. It is also safe and effective. There was no recurrence or complications recorded during the one-year follow-up, apart from a Tenon granuloma that was excised. The injections are safe and effective when combined with intraoperative application to the conjunctival fornix.

The abstract can be found in the latest edition of the journal Clinical Ophthalmology.

Related Videos
Josefina Botta, MD, MSc, at ASCRS 2024
Dr Nir Shoham Hazon, Director, Miramichi EyeNB Centre of Excellence, New Brunswick, Canada
J. Morgan Micheletti, MD, speaks at the 2024 ASCRS meeting
Dr William Wiley of Cleveland Eye Clinic, Northeast Ohio
© 2024 MJH Life Sciences

All rights reserved.